Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 10;5(11):1873–1887. doi: 10.1002/hep4.1767

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

FIG. 4 — Analysis of HBsAg IC dynamics in the REP 401 study. Anti‐HBs (top row) and ALT dynamics (bottom row) are provided for comparison with HBsAg IC dynamics (middle row). Individual responses for all control (left) and experimental (middle left) participants during the first 48 weeks of treatment, for all participants achieving HBsAg < 1 IU/mL during 48 weeks of NAP therapy (middle right) and maintaining HBsAg < 1 IU/mL after removal of all therapy (right) are provided. Participants with HBsAg IC “flares” (01‐007 and 02‐050) are identified (see also insets). Participants with continuous increases in HBsAg IC during therapy and follow‐up (n = 4) are identified in bold (top, middle) and in inset (*, bottom). Treatment paradigms are indicated at the top (see also Fig. 2A). Anti‐HBs and ALT data were previously published.⁽ ¹⁹ ⁾ Anti‐HBs and HBsAg IC responses in all participants experiencing viral rebound during follow‐up are presented in Supporting Fig. S2.